Literature DB >> 2644259

Human immunodeficiency virus protease. Bacterial expression and characterization of the purified aspartic protease.

P L Darke1, C T Leu, L J Davis, J C Heimbach, R E Diehl, W S Hill, R A Dixon, I S Sigal.   

Abstract

The protease of human immunodeficiency virus has been expressed in Escherichia coli and purified to apparent homogeneity. Immunoreactivity toward anti-protease peptide sera copurified with an activity that cleaved the structural polyprotein gag p55 and the peptide corresponding to the sequence gag 128-135. The enzyme expressed as a nonfusion protein exhibits proteolytic activity with a pH optimum of 5.5 and is inhibited by the aspartic protease inhibitor pepstatin with a Ki of 1.1 microM. Replacement of the conserved residue Asp-25 with an Asn residue eliminates proteolytic activity. Analysis of the minimal peptide substrate size indicates that 7 amino acids are required for efficient peptide cleavage. Size exclusion chromatography is consistent with a dimeric enzyme and circular dichroism spectra of the purified enzyme are consistent with a proposed structure of the protease (Pearl, L.H., and Taylor, W.R. (1987) Nature 329, 351-354). These data support the classification of the human immunodeficiency virus protease as an aspartic protease, likely to be structurally homologous with the well characterized family that includes pepsin and renin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2644259

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH.

Authors:  D Xie; S Gulnik; E Gustchina; B Yu; W Shao; W Qoronfleh; A Nathan; J W Erickson
Journal:  Protein Sci       Date:  1999-08       Impact factor: 6.725

2.  Production of cytotoxic proteins in Escherichia coli: a fermentation process for producing enzymatically active HIV-1 protease.

Authors:  W K Herber; F J Bailey; C E Carty; J C Heimbach; R Z Maigetter
Journal:  Appl Microbiol Biotechnol       Date:  1991-11       Impact factor: 4.813

3.  Novel method for probing the specificity binding profile of ligands: applications to HIV protease.

Authors:  Woody Sherman; Bruce Tidor
Journal:  Chem Biol Drug Des       Date:  2008-03-31       Impact factor: 2.817

4.  Isolation and characterization of recombinant Drosophila Copia aspartic proteinase.

Authors:  Senarath B P Athauda; Katsuji Yoshioka; Tadayoshi Shiba; Kenji Takahashi
Journal:  Biochem J       Date:  2006-11-01       Impact factor: 3.857

5.  3'-Tetrahydrofuranylglycine as a Novel, Unnatural Amino Acid Surrogate for Asparagine in the Design of Inhibitors of the HIV Protease.

Authors:  Wayne J Thompson; Arun K Ghosh; M Katharine Holloway; Hee Yoon Lee; Peter M Munson; John E Schwering; Jenny Wai; Paul L Darke; Joan Zugay; Emilio A Emini; William A Schleif; Joel R Huff; Paul S Anderson
Journal:  J Am Chem Soc       Date:  1993-01-01       Impact factor: 15.419

6.  Isolation of mutants of human immunodeficiency virus protease based on the toxicity of the enzyme in Escherichia coli.

Authors:  E Z Baum; G A Bebernitz; Y Gluzman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

7.  Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain.

Authors:  G Zybarth; H G Kräusslich; K Partin; C Carter
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation.

Authors:  Ozlem Equils; Alan Shapiro; Zeynep Madak; Chunren Liu; Daning Lu
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles.

Authors:  J Park; C D Morrow
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

10.  Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions.

Authors:  D A Davis; K Yusa; L A Gillim; F M Newcomb; H Mitsuya; R Yarchoan
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.